Esperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of $0.22, $0.07 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $168.45 million versus the consensus estimate of $168.28 million.

2026 Financial Outlook

The Company expects full year 2026 operating expenses to be in the range of $225 million to $255 million, including approximately $15 million in non-cash expenses related to stock compensation.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.